Fusco et al., 2023 - Google Patents
Short-chain fatty-acid-producing bacteria: key components of the human gut microbiotaFusco et al., 2023
View HTML- Document ID
- 6567839977405871070
- Author
- Fusco W
- Lorenzo M
- Cintoni M
- Porcari S
- Rinninella E
- Kaitsas F
- Lener E
- Mele M
- Gasbarrini A
- Collado M
- Cammarota G
- Ianiro G
- Publication year
- Publication venue
- Nutrients
External Links
Snippet
Short-chain fatty acids (SCFAs) play a key role in health and disease, as they regulate gut homeostasis and their deficiency is involved in the pathogenesis of several disorders, including inflammatory bowel diseases, colorectal cancer, and cardiometabolic disorders …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fusco et al. | Short-chain fatty-acid-producing bacteria: key components of the human gut microbiota | |
| Croci et al. | Dietary strategies for management of metabolic syndrome: role of gut microbiota metabolites | |
| Oniszczuk et al. | Role of gut microbiota, probiotics and prebiotics in the cardiovascular diseases | |
| Coppola et al. | The protective role of butyrate against obesity and obesity-related diseases | |
| Ji et al. | Gut microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease (NAFLD) | |
| Gasaly et al. | Butyrate and the fine-tuning of colonic homeostasis: implication for inflammatory bowel diseases | |
| Sanchez-Rodriguez et al. | The gut microbiota and its implication in the development of atherosclerosis and related cardiovascular diseases | |
| Vernocchi et al. | Gut microbiota metabolism and interaction with food components | |
| Rosca et al. | Capsaicin and gut microbiota in health and disease | |
| Noce et al. | Impact of gut microbiota composition on onset and progression of chronic non-communicable diseases | |
| Forte et al. | Obesity affects the microbiota–gut–brain axis and the regulation thereof by endocannabinoids and related mediators | |
| Jazani et al. | Impact of gut dysbiosis on neurohormonal pathways in chronic kidney disease | |
| Lopez-Santamarina et al. | Probiotics as a possible strategy for the prevention and treatment of allergies. A narrative review | |
| Szczyrek et al. | Diet, microbiome, and cancer immunotherapy—A comprehensive review | |
| Effendi et al. | Akkermansia muciniphila and Faecalibacterium prausnitzii in immune-related diseases | |
| Schierová et al. | Gut microbiome changes in patients with active left-sided ulcerative colitis after fecal microbiome transplantation and topical 5-aminosalicylic acid therapy | |
| D’Aquila et al. | Gut microbiota as important mediator between diet and DNA methylation and histone modifications in the host | |
| Van Krimpen et al. | The effects of pro-, pre-, and synbiotics on muscle wasting, a systematic review—Gut permeability as potential treatment target | |
| Alsharairi | The role of short-chain fatty acids in the interplay between a very low-calorie ketogenic diet and the infant gut microbiota and its therapeutic implications for reducing asthma | |
| Mertowska et al. | A link between chronic kidney disease and gut microbiota in immunological and nutritional aspects | |
| Islam et al. | The role of gut microbiota and metabolites in obesity-associated chronic gastrointestinal disorders | |
| Murphy et al. | Exploring the gut microbiota and cardiovascular disease | |
| Hata et al. | Gut microbiota changes by an SGLT2 inhibitor, luseogliflozin, alters metabolites compared with those in a low carbohydrate diet in db/db mice | |
| Zheng et al. | Chinese propolis prevents obesity and metabolism syndromes induced by a high fat diet and accompanied by an altered gut microbiota structure in mice | |
| Hawryłkowicz et al. | Patient nutrition and probiotic therapy in COVID-19: what do we know in 2021? |